ABSTRACT
A 44-year-old male patient developed proptosis, edema, and erythema progressing to complete ptosis and supraduction deficit 2 days after positive COVID-19 test. He failed to improve on systemic antibiotics. MRI showed thickening and T2 enhancement of the superior rectus/levator complex consistent with orbital myositis. He improved on intravenous corticosteroids and experienced continued gradual improvement on oral steroids.
Subject(s)
COVID-19 , Exophthalmos , Orbital Myositis , Adult , Exophthalmos/diagnosis , Exophthalmos/drug therapy , Exophthalmos/etiology , Humans , Male , Oculomotor Muscles/diagnostic imaging , Orbital Myositis/diagnostic imaging , Orbital Myositis/drug therapy , SARS-CoV-2Subject(s)
COVID-19/complications , Mucormycosis/diagnosis , Rhizopus oryzae/isolation & purification , Adult , COVID-19/immunology , Exophthalmos/diagnosis , Fatal Outcome , Humans , Immunocompromised Host , Male , Mucormycosis/drug therapy , Mucormycosis/microbiology , Mucormycosis/surgery , Ophthalmoplegia/diagnosis , Rhizopus oryzae/physiology , COVID-19 Drug TreatmentABSTRACT
During the current pandemic of COVID-19, a myriad of manifestations and complications has emerged and are being reported on. We are discovering patients with COVID-19 are at increased risk of acute cardiac injury, arrythmias, thromboembolic complications (pulmonary embolism and acute stroke), and secondary infection to name a few. I describe a novel case of COVID-19 in a previously healthy 33-year-old female who presented for altered mental status and proptosis. She was ultimately diagnosed with mucormycosis and orbital compartment syndrome, in addition to COVID-19. Early identification of these high morbidity conditions is key to allow for optimal treatment and improved outcomes.